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ABSTRACT: Background: Metastasis to the pituitary gland is unusual, and occurs most often in patients with carcinomas of the breast 
or lung. Despite its propensity for spread to the brain, metastatic melanoma has rarely been described within the sella. Methods: We 
report two cases of malignant melanoma pathologically confirmed within the pituitary, both metastatic from a primary site on the chest 
wall. In each patient, transsphenoidaI resection of the tumor was incomplete and each received local radiotherapy after surgery. Results: 
One patient recurred quickly and developed brain metastasis as well. He died four months after resection of the pituitary metastasis, but 
the second patient survived six months without recurrence. As intrasellar metastasis portends widespread systemic disease and may be 
synchronous with parenchymal brain metastasis, survival in such patients is limited regardless of adjunctive therapy. Conclusions: Such 
cases are likely to arise more commonly in future due to the increasing incidence of melanoma. Identifying them by imaging alone is 
difficult due to inconsistent signal characteristics on MRI (as shown by these cases) and the confusion introduced by any associated 
intratumoral hemorrhage. 
RESUME: Metastase pituitaire d'un melanome. Les metastases it l'hypophyse sont rares et surviennent la plupart du temps chez des patients porteurs 
d'un cancer du sein ou du poumon. Bien que Ie melanome ait tendance it metastaser au cerveau, une metastase it la selle turcique a rarement ete Mcrite. 
Methodes: Nous rapportons deux observations cliniques de melanome malin dans I'hypophyse, confirmes en anatomopathologie. La tumeur primitive 
dans les deux cas etait situee sur Ie thorax. La resection transsphenoYdale a ete incomplete chez les deux patients et ils ont re'ru de la radiotherapie locale 
apres la chirurgie. Resultats: Un patient a eu une recidive peu de temps apres et il a presente egalement des metastases cerebrales. Il est dt5ct5de quatre 
mois apres la resection de la metastase pituitaire. Le deuxieme patient a survecu six mois sans recidive. Etant donne qu'une metastase intrasellaire 
laisse pre sager une maladie systemique disseminee et peut coincider avec des metastases cerebrales parenchymateuses, la survie de ces patients est 
limitee, quel que soit Ie traitement d'appoint. Conclusions: Com me l'incidence du melanome augmente, ces cas seront de plus en plus frequents. II 
est difficile de les identifier seulement par I'imagerie it cause de caracteristiques variables du signal it I'IRM, ce qui etait Ie cas chez nos patients, et de 
l'association possible d'une hemorragie intratumorale, ce qui introduit un facteur de confusion. 
Due to the increasing incidence of melanoma, patients with 
metastasis to all systemic sites (including unaccustomed or 
uncommon locations) are now more frequently seen. Among 
these, metastasis to the pituitary has occurred in only a handful 
of cases.'·6 We report two patients with melanoma involving the 
pituitary, both with prior melanoma already established in 
extrapituitary locations. Because pituitary adenomas are 
common in the popUlation at large, oncologists often assume that 
a sellar tumor in a patient with melanoma is a pituitary adenoma. 
The autopsy series of Max et al7 showed that in patients with 
metastatic cancer a sellar lesion is actually twice as likely to be 
a benign pituitary adenoma as a metastasis. The characteristic 
MRI features of melanin, if present, would allow a sellar tumor 
to be identified as a melanocytic neoplasm, but they are not 
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infallible and surgery may still be needed for biopsy and 
decompression. Although the assumption of a pituitary adenoma 
may often be correct, these two cases are presented to emphasize 
From the Departments of Neurosurgery OEM). Endocrine Neoplasia and Honnonal 
Disorders (SGW). Pathology (GNF). The University of Texas M. D. Anderson Cancer 
Center. Houston. Texas; Department of Neurosurgery (WTC). University of Utah 
School of Medicine, Salt Lake City. Utah. USA. 
RECEIVED OCTOBER 24, 2005. ACCEPTED IN FINAL FORM APRIL 29,2007. 
Reprint requests to: Ian E. McCutcheon. Department of Neurosurgery. The University 
of Texas M. D. Anderson Cancer Center. 1515 Holcombe Blvd., Unit 442, Houston. 
Texas. 77030. USA. 
r ; 
that patients who carry both systemic melanoma 
and a sellar tumor may harbor melanoma within 
the sella; and that melanoma may present as a 
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A 77-year-old male had wide local excision 
of melanoma (Clark level IV, Breslow's 
thickness 1.2 mm) of the anterior chest wall, 
without lymph node sampling. Thirty-three 
months later he developed ptosis and diplopia 
and had by exam oculomotor and abducens 
palsies on the left. Endocrine workup showed 
low levels of gonadotrophic hormones but other 
pituitary hormonal axes were intact. 
Ophthalmological exam showed full visual 
fields and visual acuity of 20/30 in the right eye 
and 20170 in the left. On MRI a tumor centered 
on the sella was present which extended into 
both cavernous sinuses and the upper clivus 
Figure 1: MRI of sella, Case I, coronal view: (A) Tl-weighted image, post-contrast 
and (B) 72-weighted image. Bilateral cavernous sinus invasion is present, but no 
suprasellar extension, and the pituitary stalk appears intact. As hypointensity on 12-
weighted imaging is typical for melanoma, the opposite signal displayed in this patient 
confounded the diagnosis prior to surgery. 
[Figure 1]. After transsphenoidal surgery, during 
which subtotal resection of a fleshy, vascular, 
pigmented tumor was achieved, the cranial neuropat.hies did not 
improve and visual acuity was stable. InvaSIOn of the 
adenohypophysis by tumor was noted at surgery. Pathological 
examination revealed a poorly differentiated melanoma (staining 
positive for HMB-45 and for S-100 protein) with bone invasion. 
Staging workup failed to reveal any other areas of metastasis. 
Intensity-modulated radiotherapy was given to the sella and 
parasellar area to control residual tumor within the cavernous 
sinuses and clivus. The patient was alive six months after 
surgery with no further growth of tumor evident, and no other 
intracranial metastases. 
ease 2 
A 42-year-old male presented with melanoma (Clark level IV, 
Breslow's thickness 3 mm) of the anterior chest wall, and was 
treated with wide local excision and axillary node dissection that 
revealed 0115 nodes positive for tumor. He was free of disease 
for 77 months, and then developed two new subcutaneous 
nodules on his chest representing metastatic melanoma. Staging 
workup showed cervical and hilar lymphadenopathy and 
metastasis to lung and to retroperitoneum. Magnetic resonance 
imaging revealed an intrasellar tumor, 2.5 cm in maximum 
Figure 2: MRI of sella, Case 2,. (A) Coronal view, Tl-weighted, post-contrast (B) S~gitta{ view, Tl -w,eighted, post-c~ntrast. fC) 
Coronal view, 72-weighted. The tumor shows a dumb-bell shape and significant chlasmal compressIOn, tog.et~er with pOSSible 
invasion of the left cavernous sinus. The normal pituitary gland is not distinguishable from tumor. The low to Isollltense 12 Signal 
is more consistent with melanoma than with pituitary adenoma. 
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Figure 3: Smear preparation (upper left panel) shows an epithelioid round cell neoplasm with 
moderate pleomorphism. In the corresponding tissue section (upper right panel), the tumor is 
organized in sheets and lobules. Immunohistochemical staining for melanoma antigens (bottom left 
panel) shows strong tumor cell reactivity (left half of panel), with lack of staining in entrapped pituitary 
acini (right half of panel). In contrast, a serial section immunostained for synaptophysin (bottom right 
panel) shows strong positivity in normal pituitary acini (right half of panel), with no reactivity in the 
metastatic melanoma (left half of panel). Upper left panel, H&E, x 400; upper right panel, H&E, x 
200; bottom left panel, melanoma antigen cocktail immunostain with hematoxylin counterstain, x 40; 
bottom left panel, synaptophysin immunostain with hematoxylin counterstain, x 40. The melanoma 
antigen cocktail comprises antibodies against Mart 1 (clone Ab3), dilution 1:100; HMB-45, dilution 
1 :50; and tyrosinase (clone T3Jl), dilution 1:20. 
diameter, with suprasellar extension and chiasmal compression 
[Figure 2]. As in Case 1. the radiological interpretation 
considered the history of melanoma and raised the possibility of 
metastasis, but considered pituitary adenoma more likely. 
Symptoms of central hypocortisolism and hypogonadism were 
present, as well as diabetes insipidus, but formal endocrine 
workup was not completed due to the urgent need to achieve 
decompression of the optic apparatus. Ophthalmological 
examination showed an incomplete right temporal hemianopia 
with visual acuity of 20/400 OD and 20/60 OS. At 
transsphenoidal surgery, the dura of the sellar floor was grossly 
invaded by tumor. Within the sella, hypervascular, friable, 
pigmented tissue was encountered and subtotally resected to 
achieve decompression of the optic apparatus. Pathological 
examination of the tumor showed melanoma; tumor cells were 
synaptophysin-negative, but stained positive for HMB-45 
[Figure 3]. No necrosis was seen, but occasional mitotic figures 
were seen. After surgery, deficiencies of thyrotropin, 
adrenocorticotropin, gonadotropins, and vasopressin were 
confirmed. After initial improvement in vision, it relapsed to the 
preoperative level and he received whole-brain radiotherapy (30 
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Gy in 10 fractions). He was treated with thalidomide and 
temozolomide with resulting decrease in the size of the pituitary 
and lung metastases. However, new brain metastasis developed 
two months after surgery, and he died of widespread metastasis 
four months after that. 
DISCUSSION 
Metastasis to the pituitary gland is uncommon overall, with 
the majority occurring in patients with carcinomas of the lung or 
breast. Many such tumors produce no symptoms during life, but 
metastatic deposits are found at autopsy in the pituitary glands of 
up to 5% of subjects with systemic cancer.8 Premortem diagnosis 
typically follows the development of hypopituitarism, visual 
loss, or diplopia from cavernous sinus involvement, but can be 
difficult as the constitutional symptoms of systemic cancer can 
mimic those of anterior pituitary dysfunction.9 Diabetes 
insipidus is seen at presentation in 45-70% of these patients, with 
others developing it later in the course of the disease.8,9 
Although both of the patients reported here had symptoms of 
paraseUar compression and partial anterior hypopituitarism, only 


















Table: Patients with melanocytic tumors within the sella 
Preop endocrine 
Age/sex Extrasellar primary deficits 01 
Primary sellar meianocytoma / 
benign 
Neilson et al 1963'· 621M none TSH, ACTH, FSH/LH no 
Scholtz and Siu 197617 54/M none ? ? 
Kasumova and Imauri 1980'8 361M none ? ? 
Chappell et al 1990" 351F none ? no 
Rousseau et al 2005'" 251F none ACTH no 
Primary sellar melanoma / malignant 
Roos 196323 44/F none TSH, ACTH yes 
Copeland et al 1980'" 37/F none ? no 
Aubin et al 199y-25 47/M none TSH, FSH/LH, ACTH SIAOH 
Tutenberg et al 2004"" 37/F none TSH, FSH/LH no 
Jacob et al 200627 631F none none no 
Metastatic melanoma 
Cox and Sloan 1924' 54/M jejunum ? yes 
Girdwood 19282 421F skin (multiple) ? yes 
Schurmeyer and Bettrnann 19563 31/F skin (back) ? no 
Clifford et al 1968' 64/M 
spinal cord 
(unproven)- ? ? 
Mayr et al 1993' 251M ? TSH no 
Leung et al 20046 461M skin (neck) TSH, FSH/LH yes 
McCutcheon et al 2006 (case 1) 791M skin (chest) FSH/LH no 
McCutcheon et al 2006 (case 2) 49/M skin (chest) TSH, FSH/LH, ACTH no 
Non-melanocytic tumors showing melanin production Tumor type 
Harris et a11999" craniopharyngioma (2 cases) 
teratoma containing melanotic prognoma (1 
Tobo et aI1981" case) 
*Tumor originated above the sella but on recurrence was intrasellar 
**Marked necrosis and mitotic activity; at autopsy had liver metastasis and leptomeningeal involvement by tumor 
***Multiple skin nevi were incompletely examined 
Brain HMB-
rnets Surgery XRT Chemo 451MIB-1 Follow-up/mos 
no no no no 0/36 
no yes no no 0/0.5 
no yes no no Al72 
no yes no no N3 
positive I 
no yes no no 3% N24 
no yes no no 0/15 
LMO yes no yes 0/41 
no yes yes no positive 0/16 
positive I 
no yes yes no 15-30% N24 
no yes yes no positive Of'weeks" 
yes no no no 0/6 
yes no no no 0/1 
no no no no O/unknown 
yes no no no O/unknown 
yes ? ? ? Nunknown 
no yes yes no positive AI7 
no yes yes no positive N6 
yes yes yes yes positive 0/6 
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Because melanoma so rarely appears in the sella, tumors 
found there during oncologic staging (or after scans prompted by 
headache or visual loss) are most commonly coincidental 
pituitary adenomas rather than metastases. Distinguishing an 
adenoma from a melanoma is uncertain at best, as both can 
invade the cavernous sinus, sphenoid bone, or clivus, and both 
can show intratumoral hemorrhage. Melanotic melanomas by 
MRI show high signal on Tl-weighted images and low signal on 
T2, but interpretation of images may be confounded by the 
presence of intratumoral or peri tumoral hemorrhage of varying 
ages, and intracellular methemoglobin shows similar 
characteristics to melanin.10 Our Case 1 showed hyperintensity 
on T2, which confounded the preoperative diagnosis [Figure 1], 
but Case 2 did show low signal on such sequences [Figure 2]. In 
the absence of hemorrhage or cyst fluid within the tumor, 
pituitary adenomas theoretically differ from melanoma by 
showing mild hyperintensity on T2 (80%) and hypointense 
signal on Tl.lI As these proportions vary by secretory SUbtype, 
and by melanin or methemoglobin content, general statistics may 
be misleading in individual patients. 12.13 An MRI can suggest 
that an intrasellar tumor is melanocytic in nature, but only 
pathological examination can prove it. 
Melanocytic tumors within the sella have been infrequently 
reported, and significant confusion exists in the terminology and 
classification of such neoplasms. We propose that they most 
logically divide into four categories: (1) melanocytomas, which 
follow a benign and indolent clinical course, much like many 
pituitary adenomas; (2) primary malignant melanomas, 
associated with no identifiable extrapituitary site of origin, 
displaying a tendency to enlarge more rapidly, and capable of 
metastasis; (3) malignant melanomas metastatic to the sella, with 
a known primary site in the skin, eye, or elsewhere; and (4) non-
melanocytic tumors showing melanin production. This last 
category is very rarely seen, but craniopharyngiomas containing 
melanin have been reported,14 as has a case of teratoma 
containing melanotic prognoma (a tumor usually seen in the 
infant maxilla).15 Our analysis excludes tumors arising in 
parasellar locations like the cavernous sinus, and focuses 
exclusively on those that involve the pituitary gland. 
Although melanocytomas occasionally occur in the 
intracranial compartment, typically in association with the 
leptomeninges, only five cases (Table) have been reported which 
arose unequivocally within the sella. I6-20 These tend not to be 
associated with diabetes insipidus, but anterior pituitary deficits 
are sometimes seen, and extended survival is possible. 
Melanocytes exist most densely over the ventrolateral medulla, 
but small clusters can be found anywhere along the 
leptomeninges.21 Despite a report of melanocyte clusters within 
the pars intermedia in Zucker rats, the pattern of leptomeningeal 
distribution of such clusters differs from that seen in man, and 
intrapituitary melanocytes have yet to be detected in the human 
pituitary.22 Thus, the cell of origin of intrasellar melanocytomas 
is uncertain. 
Malignant melanomas have five times been reported in the 
sella without a known primary sitep·27 It is impossible to say 
whether such tumors are truly primary to the sella, whether they 
represent instances in which a melanoma elsewhere flourished 
long enough to metastasize before undergoing involution, or 
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whether the search for an extrasellar primary tumor was simply 
inadequate. These tumors show such hallmarks of malignancy as 
marked necrosis, high MIB-l labeling indices, and frequent 
mitotic figures, and lead to the patient's demise in spite of 
aggressive treatment with surgery, local irradiation, andlor 
chemotherapy. None of the cases in the literature was associated 
with diabetes insipidus, but again anterior pituitary deficits are II 
seen. The cells of these tumors stain positively for the HMB-45 
antigen, as do those of melanocytomas and metastatic 
melanomas. In this category, only the case reported by Aubin et 
al had extracerebral metastasis, a hepatic nodule that did not ~ 
appear until ten months after the initial surgery.25 
Our patients both present a clear example of melanoma 
metastatic to the sella from a primary extrapituitary location. Six 
such cases have previously been reported with clinical detail, and 
only two within the past 25 years. I -6 Such patients are also 
extremely rare at autopsy. In the series of Hagerstrand and 
Schonebeck encompassing 763 autopsy patients with cancer, 29 
had metastasis to the pituitary of which two were melanomas.28 
In another such series compiled by Schreiber et aI, 737 autopsy 
patients gave rise to 26 pituitary metastases, none of which were 
melanomas.29 Melanoma metastases are mentioned in very small 
numbers and without description by other authors,1·9.3o and in the 
largest surgical series of metastases to the sella published to date 
by Morita et aI, none of the resected tumors was a melanoma.31 
The metastasis may originate in any of the typical locations 
for melanoma (skin, gut) and here, as with other metastatic 
histologies, diabetes insipidus is common. In the only other case 
to have undergone surgery (followed by adjuvant radiotherapy), 
the patient was alive and well seven months later;6 earlier 
untreated cases imply a natural history similar to that seen for 
untreated cases of cerebral metastasis. This is not surprising, as 
concomitant brain metastasis was observed in half the extant 
cases and occurred synchronously in our Case 2. In our patients, 
a transsphenoidal approach allowed subtotal excision, as the 
tumor was intimately adherent and invasive to the normal 
pituitary and the adjacent dura. Accordingly, we followed with 
limited-field radiotherapy (which was unsuccessful in shrinking 
the tumor) and in our second case, with chemotherapy designed 
to achieve some measure of penetration through the blood-brain 
barrier. The chemotherapy did cause tumor shrinkage but failed 
to prevent new brain metastases or further spread of his already 
widely scattered systemic disease. Stereotactic radiosurgery was 
not feasible given the close proximity of the tumor to the optic 
apparatus, but might have given better local control had the 
situation permitted its use. 
An aggressive attempt at resection is advisable in these 
difficult neoplasms. If melanoma is suspected preoperatively 
from MRI signal characteristics, conclusions before surgery as to 
the malignancy of the lesion are premature; the tumor may prove 
to be an indolent melanocytoma requiring no further therapy, or 
an anaplastic melanoma needing strenuous further effort at local 
and systemic control. A careful search for concomitant brain 
metastasis may disclose lesions implying a malignant phenotype 
within the sella. However, it is always possible for a patient to 
harbor both a brain metastasis and a pituitary adenoma. 
r 
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